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Background: Although various microRNAs (miRNAs) regulate immune and inflammatory responses, the function of
miRNAs in periodontitis has not been clearly illuminated. In this study, we measured miRNA-146 (miRNA-146a and
miRNA-146b-5p) expression and explored its regulatory function in the inflammatory response in human gingival
fibroblasts (HGFs).
Methods: miRNA-146a and miRNA-146b-5p expression was measured by performing real-time polymerase chain
reaction in HGFs after Porphyromonas gingivalis (p.g) lipopolysaccharide (LPS) stimulation. After the HGFs were
transfected with miRNA-146a and miRNA-146b-5p inhibitor, the expression levels of interleukin-1β (IL-1β),
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay
(ELISA). Meanwhile, IL-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) were
detected by western blot and quantitative PCR. A luciferase assay was used to detect whether miRNA-146 could
directly bind to the 3’-UTR of IRAK1.
Results: The expression levels of miRNA-146a and miRNA-146b-5p significantly increased in the P.g LPS-stimulated
HGFs compared to the non-stimulated HGFs. The inhibition of miRNA-146a and miRNA-146b-5p resulted in
increased IL-1β, IL-6 and TNF-α secretion. The mRNA and protein levels of IRAK1, but not TRAF6, also increased. We
further found that miRNA-146a and miRNA-146b-5p directly bound to the IRAK1 3’-UTR.
Conclusion: Our data suggest that miRNA-146 inhibits pro-inflammatory cytokine secretion through IRAK1 in HGFs,
which indicates that miRNA-146 functions as a negative regulator of periodontal inflammation.
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Periodontal disease is induced by a group of pathogenic
microorganisms, such as Porphyromonas gingivalis (P.g),
which leads to inflammation and the destruction of peri-
odontal tissues. The innate immune response is the most
important line of defense against putative periodontal
pathogens and virulence factors, such as P.g and P.g LPS
[1]. Human gingival fibroblasts (HGFs), which are the
major components of gingival connective tissue, directly
interact with bacteria and bacterial products, including
LPS, in periodontitis [2].* Correspondence: shurong123@hotmail.com
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reproduction in any medium, provided the ormicroRNAs (miRNAs) are an abundant class of short
(20 to 25 nucleotides), non-coding RNA molecules. They
function as post-transcriptional regulators that bind to
complementary sequences in the 3' untranslated regions
(3' UTRs) of target messenger RNA transcripts (mRNAs),
usually resulting in gene silencing [3,4]. miRNAs are im-
plicated in establishing and maintaining the cellular fate of
immune cells and are involved in innate immunity by
regulating Toll-like receptor signalling and ensuing a cyto-
kine response [5]. Recent studies have reported different
miRNA expression patterns between healthy tissues and
inflamed tissues inflicted with periodontal disease, which
indicates that miRNAs may be involved in the regulation
of periodontal disease [6,7]. However, the function of
miRNAs in HGFs during periodontitis remains unclear.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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146b-5p. It has been demonstrated that miRNA-146a and
miRNA-146b-5p are involved in inflammation in tissues
in addition to gingival tissue [8,9]. Recent studies reported
that interleukin-1 receptor-associated kinase 1 (IRAK1)
and tumor necrosis factor receptor-associated factor 6
(TRAF6) are direct targets of miRNA-146 [10]. Based on
these reports, we wondered whether miRNA-146 affected
the gingival inflammatory response though IRAK1 and
TRAF6.
In this study, we report that miRNA-146a and miRNA-
146b-5p are up-regulated in response to P.g LPS stimula-
tion in HGFs. We also showed that miRNA-146 inhibition
results in an increase in pro-inflammatory cytokines, such
as IL-1β, IL-6 and TNF-α, through IRAK1 activation. We
found that miRNA-146 inhibits IRAK1 expression by
binding directly to the 3’-UTR of IRAK1. Our data suggest
that miRNA-146 is a negative regulator of the immune re-
sponse in periodontal disease.
Methods
Primary cell culture of HGFs
Approval for conducting the experiments on the human
tissue specimens was obtained from the Committee of Eth-
ics in Research of the School of Medicine, Shanghai Jiao
Tong University. After informed consent was obtained
from each dental patient undergoing oral surgery, the
discarded gingiva was collected. The explants of the gingiva
were obtained from 10 patients (4 males and 6 females
aged from 26 to 63 years old) who were nonsmokers and
did not have any systemic diseases. Apart from periodontal
scaling and root planning treatment, the subjects did not
receive other treatments or take any prescribed medica-
tion. The epithelial tissues were separated from the gingiva
after 24 hours of soaking in 2 U/ml of Dispase II (Takara,
Japan). The gingival connective tissues were cut into pieces
and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, USA) supplemented with 20% fetal
bovine serum (FBS) (Hyclone, USA) and antibiotics
(50 μg/ml of streptomycin sulfate, 100 U/ml of penicil-
lin) [11]. The medium was changed every 3 days for
10–20 days. The cells were passaged when confluent
cell monolayers were formed [12].
RNA extraction
After 4 passages, total RNA was extracted from the HGFs
using TRIzol reagent (Invitrogen, USA) according to the
manufacturer’s protocol. The RNA was stored at −80°C
until further use. For the commercial miRNA microarray
analyses (Kangchen Bio-Tech, Shanghai, China), RNA was
extracted from pooled HGFs that were stimulated with
1 μg/ml of P.g LPS (Invivogen, USA) or unstimulated for
24 hours. For quantitative RT-PCR analyses, the RNA
from individual subjects was used.miRNA microarray analyses
HGFs were cultured for 4 serial passages in DMEM
supplemented with 10% FBS and used in the micro-
array analyses. HGFs were cultured with DMEM and
10% FBS in the presence or absence of 1 μg/ml of P.g
LPS (Invivogen, USA) for 24 hours. microRNA profil-
ing analysis was performed by Kangchen Bio-Tech.
Briefly, the miRNAs in the RNA samples were labeled
using the miRCURY™ Hy3™/Hy5™ Power Labeling Kit
(Exiqon, Denmark). The labeled miRNAs were detected
by hybridization to miRNA microarrays containing 1769
capture probes (miRCURYTM Array microarray kit,
v.11.0, Exiqon) on Bioarray LifterSlip coverslip slides
(Genetimes Technology, Shanghai, China). After washing
and then drying by centrifugation, the slides were scanned
using a Genepix 4000B microarray scanner with a 635 nm
laser (Molecular Devices, USA). The fluorescent density
data in the images were analysed using Genepix Pro 6.0
software (Molecular Devices) and are presented as the
n-fold change of fluorescent density in LPS-stimulated
HGFs (LPS+) after normalization with the untreated
HGFs (LPS-).
Reverse transcription
Total RNA was reverse transcribed into cDNA using
gene-specific reverse transcription (RT) primers and the
MMLV Reverse Transcriptase First Strand cDNA Syn-
thesis Kit (Epicentre, Madison, USA). The RT primers
were designed according to the miRNA sequences in the
Sanger miRBase. Gene-specific stem-loop primers are
listed as follows: hsa-miRNA-146a: GTCGTATCCAGT
GC GTGTCGTGGAGTCGGCAATTGCACTGGATAC
GACaaccca; hsa-miRNA-146b-5p: GTCGTA TCCAGT
GCGTGTCGTGGAGTCGGCAATTGCACTGGATAC
GACagccta. Each reaction mixture contained 2 μg of
DNase-treated total RNA, 50 nM of the RT primers,
1× reaction buffer, 0.25 mM of each dNTP, 200 U of
MMLV reverse transcriptase, 20 U of ScriptGuard™
RNase inhibitor, and nuclease-free water (Epicentre) in
a total volume of 20 μl. The reaction was performed at
16°C for 30 min, 42°C for 30 min, and 85°C for 5 min
in an Applied Biosystems 9700 thermocycler (Applied
Biosystems, USA).
Real-time polymerase chain reaction (PCR)
Real-time PCR was performed as previously described
[7]. Briefly, SYBR Green qPCR Master Mix (PA-112,
SAbiosciences, Qiagen) was used to detect the levels
of miRNA-146a and miRNA-146b-5p on an Applied
Biosystems 7900HT Sequence Detection System (Applied
Biosystems). The U6 small nuclear RNA (NR_003027)
was used as an internal control. Each reaction contained
5 μl of RT SYBR Green qPCR Master Mix, 1.5 μM of the
specific forward PCR primer that binds to the 5’ portion
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primer that binds to a sequence located in the stem-loop
structure, and nuclease-free water in a total volume of
10 μl. The reactions were performed at 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s, 60°C for 15 s, 72°C
for 15 s, and 55°C for 15 s. All experiments were repeated
three times. The sequences of the primers are listed as fol-
lows: hsa-miRNA-146a: GGGTGAGAACTGAATTCCA;
hsa-miRNA-146b-5p: GGGTGAGAACTGAATTCCA; the
universal reverse PCR primer sequence: CAGTGCGTG
TCGTGGAGT; U6 small nuclear RNA-forward: GCTT
CGGCAGCACATATACTAAAAT and U6-reverse: CGCT
TCACGAATTTGCGTGTCAT. The relative expression of
each miRNA compared to the U6 small nuclear RNA was
calculated using the 2–△△CT method [7].
miRNA inhibition
miRNA-146 inhibitors were purchased from Applied
Biosystems. After 4 passages, the HGFs were transfected
with the miRNA inhibitors or a negative control at a
concentration of 10 and 100 nM following the manufac-
turer’s protocol. Opti-MEM (Invitrogen) and Lipofectamine
2000 were purchased from Invitrogen. A total of 105 HGFs
were seeded into each well of 24-well plates, incubated
overnight and then cultured in Opti-MEM. After 6 hours
of transfection with the miRNA and 1 μl of Lipofectamine
per well, the medium was replaced with DMEM containing
10% FBS. The supernatant was harvested 18 hours later.
Flow cytometry
Annexin V and PI stains were used to analyze necrosis
and apoptosis, respectively, in HGFs using flow cytometry.
Annexin V and PI were purchased from Beyotime (China).
The cells were analyzed on a FACSCalibur flow cytometer
using CellQuest software (BD Biosciences, USA).
Enzyme-linked immunosorbent assay (ELISA)
For the analysis of cytokine production in the superna-
tants of treated and untreated HGFs, human IL-1β, IL-6,
IL-10 and TNF-α ELISA Duoset kits were purchased
from R&D Systems (USA). The plates were incubated
with the appropriate antibodies, aspirated and then
washed according to the manufacturer’s protocol. The
optical density was detected at 450 nm with a 570 nm
compensation.
Computational predication of the miRNA targets
To further analyze the functions of miRNA-146, we
used two computational approaches, MicroRNA.org
(www.microrna.org) and targetscan (www.targetscan.org),
to predict the targets of miRNA-146 in the TLR signaling
pathways [13,14]. The mirSVR algorithm tool from
MicroRNA.org was used to evaluate many features of the
identified miRNA targets, including secondary structure-based accessibility of the target site and conservation, with-
out introducing a large number of spurious predictions
[14]. The targets that were predicted by both modules and
contained acceptable mirSVR down-regulation scores were
selected for additional studies.
Western blot
Immunoblot analyses were performed using SDS-PAGE
standard protocols. 105 cells were harvested and lysed
(1 mM sodium orthovanadate, 1 mM phenylmethanes
ulfonylfluoride, 10 μg/ml aprotinin, leupeptin, and
pepstatin), with protease inhibitors in the lysis buffer
(50 mM HEPES (pH 7.0), 1% Nonidet P-40, 5 mM
EDTA, 450 mM NaCl, 10 mM sodium pyrophosphate,
and 50 mM NaF). For immunoblot analyses, antibodies
against IRAK1 and TRAF6 were obtained from Cell
Signaling Technology (USA), and the antibody against
β-actin was purchased from Sigma. HRP-labeled sec-
ondary antibodies, and super signal west pico chemilu-
minescent substrate (Pierce, USA) were used to visualize
the protein levels.
Luciferase assay
The IRAK1 3’-UTR sequence (1352 bp starting from TGA
of IRAK1) was cloned into the 3’site of the luc2 reporter
gene on the pGL4 plasmid (Promega, USA) between the
restriction sites SalI and BamHI. We co-transfected
200 ng of the reporter plasmid, 20 ng of pRL-TK-Renilla-
luciferase and the miRNA mimic (final concentration
40 nM) in HGFs using Lipofectamine 2000. After
24 hours of transfection, luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instruc-
tions. The data were normalized for transfection effi-
ciency by dividing firefly luciferase activity with the
activity of Renilla luciferase.
Statistical analysis
The results represent the mean ± standard deviation (SD).
Differences in the data were tested for statistical signifi-
cance using Student’s t-test. For all tests, p values <0.05
were considered statistically significant.
Results
miRNA-146a and miRNA-146b-5p are induced by P.g LPS
in HGFs
To explore the miRNA expression patterns in unstimu-
lated and LPS-stimulated HGFs, we performed a miRNA
microarray. As shown in Figure 1A, miRNA-146a and
miRNA-146b-5p expression levels were increased after P.g
LPS stimulation. Using real-time PCR, we confirmed 5
up-regulated and 2 down-regulated candidates, which was
consistent with the miRNA microarray data (Figure 1B).
We found that miRNA-146a and miRNA-146b-5p, which
Figure 1 miRNA-146a and miRNA-146b-5p increase after P.g LPS stimulation in HGFs. (A) The fold change of the miRNAs from the miRNA
microarray is shown in the schematic diagram. After the HGFs were cultured in the presence or absence of 1 μg/ml of P.g LPS for 24 hours, total
RNA was collected and used for the miRNA array. The fold change is calculated by dividing the LPS-stimulated samples by the LPS unstimulated
normalized samples. The left red bars show the up-regulated miRNAs, and the right blue bars show the down-regulated miRNAs. The colour
difference shows the fold change (up-regulation: from 5.0 to 1.0; down-regulation: from 1.0 to 4.0). (B) The expression levels of miRNA-146a and
miRNA-146b-5p in the pooled RNA samples using real-time PCR. The relative expression levels are presented as the fold change between the
LPS-stimulated (24 hour stimulation with 1 μg/ml of P.g LPS) and unstimulated HGFs. Black bars refer to microarray results, and grey bars refer to
the real-time quantitative RT-PCR results. (C) The expression levels of miRNA-146a and miRNA-146b-5p in 5 individual RNA samples using real-
time PCR. The relative levels are presented as the fold change between the LPS-stimulated and unstimulated HGFs. The short transverse lines
indicate the average values. **: p < 0.01.
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pression patterns. Furthermore, using real-time PCR, we
confirmed that miRNA-146a and miRNA-146b-5p in-
creased in pooled RNA samples and five individual RNA
samples after P.g LPS stimulation (Figure 1C). miRNA-
146 up-regulation in P.g LPS-stimulated cells suggeststhat miRNA-146 may regulate the gingival inflamma-
tory response.
The viability of HGFs after miRNA-146 inhibition
To test whether miRNA-146 can affect the response of
HGFs to bacteria, we used inhibitors of miRNA-146a
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levels in HGFs. The effects of miRNA-146a and miRNA-
146b-5p inhibition were measured using real-time PCR
(Figure 2A). We found that the levels of both miRNA-
146a and miRNA-146b-5p decreased 20-25% when 100
nM of the miRNA inhibitor was used. These results in-
dicate that inhibiting miRNA-146a and miRNA-146b-5p
efficiently suppresses miRNA-146a and miRNA-146b-5p
levels. We further determined whether the inhibition of
miRNA-146 affected necrosis and apoptosis in HGFs.
The results indicate that miRNA-146 inhibition has no
effect on HGF necrosis and apoptosis (Figure 2B) or
proliferation (data not shown). Therefore, miRNA-146
inhibition was used in subsequent experiments to explore
the function of miRNA-146 in HGFs.
Pro-inflammatory cytokine production is increased after
miRNA-146 inhibition
In the gingival inflammatory response, cytokines are key
regulators of periodontal inflammation [15]. Therefore, we
determined if miRNA-146 inhibition could lead to
changes in pro-inflammatory cytokine secretion. After
miRNA-146 inhibition in HGFs, the production of IL-1β,
IL-6, IL-10 and TNF-α was measured (Figure 3). IL-1β,
IL-6 and TNF-α production increased after miRNA-146a
and/or miRNA-146b-5p inhibition. However, the levels
of IL-10, an anti-inflammatory cytokine, were notFigure 2 The viability of HGFs after miRNA-146 inhibition. (A) HGFs w
and stimulated with 1 μg/ml of P.g LPS for 24 hours. Total RNA from the H
(B) The HGFs were collected and separated by FACS based on PI and Anne
apoptosis. The results shown represent one of three independent experimesignificantly altered. These data indicate that miRNA-
146 can negatively regulate pro-inflammatory cytokine
secretion.
miRNA-146 inhibits cytokine secretion by directly
regulating IRAK1 in HGFs
We next explored the mechanism of miRNA-146-induced
pro-inflammatory cytokine secretion. Using computa-
tional predications of miRNA targets in the TLR signaling
pathways, we found two key factors, IRAK1 and TRAF6,
that were potential targets for miRNA-146. To determine
if miRNA-146 affected key factors in the TLR pathways,
we used miRNA-146a and miRNA-146b-5p inhibition as-
says in HGFs measured IRAK1 and TRAF6 mRNA and
protein levels (Figure 4A and B). The results indicated that
the mRNA and protein levels of IRAK1, but not TRAF6,
increased. Densitometric analyses of the western blots re-
vealed that transfecting HGFs with miRNA-146a and/or
miRNA-146b-5p inhibitors resulted in an increase of
IRAK1, but not TRAF6, protein levels (data not shown).
These data indicate that miRNA-146 negatively regulates
pro-inflammatory cytokine secretion through IRAK1, but
not TRAF6. Furthermore, we detected a direct interaction
between miRNA146 and the IRAK1 3’-UTR. We cloned
the IRAK1 3’-UTR sequence downstream of the luciferase
reporter gene. In the luciferase assay, the miRNA-146a
and/or miRNA-146b-5p mimics reduced the luciferaseere transfected with 10 and 100 nM miRNA-146a and miRNA-146b-5p
GFs was harvested at different times for the quantitative RT-PCR assays.
xin V labeling. The numbers indicate the ratios of necrosis and
nts.
Figure 3 The inhibition of miRNA-146 increases the production of pro-inflammatory cytokines. The HGFs were transfected with or
without miRNA inhibitors when the cells were confluent. The cells were stimulated with 1 μg/ml of P.g LPS for 24 hours, and the cell
supernatants were collected for ELISA analysis. The levels of the cytokines are shown as the mean ± SD. *: p < 0.05. **: p < 0.01. Blank: no LPS
treatment; medium: 24 hours stimulation with 1 μg/ml of P.g LPS without the miRNA inhibitor; control: 24 hour stimulation with 1 μg/ml of P.g
LPS after being transfected with a negative control.
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results suggest that miRNA-146a and miRNA-146b-5p
modulate IRAK1 expression by directly targeting the
3’-UTR of IRAK1 mRNA in HGFs. Taken together,
miRNA-146 inhibits pro-inflammatory cytokine secre-
tion through IRAK1 in human gingival fibroblasts,
which indicates that miRNA-146 functions as a nega-
tive regulator in periodontal inflammation.
Discussion
Although the innate immune response can protect an or-
ganism against various pathogens, an excessive or prolonged
immune response can be harmful and can result in acute or
chronic inflammatory disorders. Thus, the cells involved in
the innate immune response must be regulated to inhibit
the occurrence of inflammation. It has been demonstrated
that miRNA-146 is involved in inflammatory processes [16].
Although the negative regulation of miRNA-146 has been
reported in THP-1 monocytes and macrophages [8,10], the
effects of miRNA-146 in P.g LPS-stimulated HGFs remain
unknown.
P.g is an important pathogenic organism in human
periodontitis, which is a chronic inflammatory disease
[15,17,18]. P.g LPS is a potent stimulator of inflammatorycytokine production and bone resorption. Lee et al. (2011)
compared healthy tissues with tissues infected with peri-
odontitis and found that miRNA-146 was involved in peri-
odontal inflammation [6]. Additionally, in our previous
study, we screened the expression of miRNAs in healthy
and periodontal-diseased gingiva and found that miRNA-
146 expression increased in periodontal-diseased gingiva
[7]. In this study, miRNA-146 expression increased in
HGFs after stimulation with P.g LPS, which further con-
firmed the previous studies [6,7].
Wang et al. (1999) [15] and Imatani et al. (2001) [19]
have shown that HGFs function as regulators of the
cytokine network in periodontal tissues and produce in-
flammatory cytokines in response to the stimulation
with bacterial cell components, such as P.g LPS. Thus,
we further explored whether miRNA-146 regulated the
secretion of inflammatory cytokines. After stimulation
with P.g LPS, HGFs secreted IL-1β, IL-6 and TNF-α,
which is consistent with other studies [15,18]. IL-1β, IL-6
and TNF-α are important inducers of inflammation. In
the present study, IL-1β, IL-6 and TNF-α levels increased
after the inhibition of miRNA-146a and/or miRNA-
146b-5p. These data indicate that miRNA-146 negatively
regulates the secretion of pro-inflammatory cytokines and
Figure 4 The attenuation of miRNA-146 enhances Toll-like receptor signaling. A: HGFs were transfected with a Cy™ 3 labeled dye as a
negative control and anti-miRNA-146a/anti-miRNA-146b-5p inhibitors. After 24 hours of stimulation with 1 μg/ml of P.g LPS, the expression levels
of IRAK1 and TRAF6 were analyzed by real-time PCR (A) and immunoblotting (B). The immunoblot shown in the figure is representative of three
independent experiments. C: We amplified the IRAK1 3’-UTR (1352 bp starting from TGA) and cloned the sequence into the 3’ site of the luc2
reporter gene on the pGL4 plasmid. We co-transfected 200 ng of the reporter plasmid, 20 ng of pRL-TK-Renilla-luciferase and indicated miRNA
mimic (final concentration 40 nM) into the HGFs. The cells were stimulated with 1 μg/ml of P.g LPS after transfection, and the luciferase activity
was measured using the Dual-Luciferase Reporter Assay System according to the manufacturer’s instructions. Medium: 24 hour stimulation with
1 μg/ml of P.g LPS without the miRNA inhibitor; control: 24 hour stimulation with 1 μg/ml of P.g LPS after being transfected with a negative
control. The expression levels are shown as the mean ± SD. *: p < 0.05.
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of the miRNA-146-mediated increase in pro-inflammatory
cytokines after P.g LPS stimulation is still unclear. Nakasa
et al. reported that miRNA-146 was induced by TNF-α and
IL-1β in the synovial tissues of patients with rheumatoid
arthritis [9]. We believe that miRNA-146 could be induced
as a result of an increase in TNF-α and IL-1β after stimula-
tion with P.g LPS; however, further confirmation is neces-
sary. In this context, miRNA-146 would regulate the
immune response in P.g LPS-stimulated HGFs.
IL-10 plays a major role in suppressing the immune
and inflammatory responses by inhibiting the activity
of Th1 cells, NK cells and macrophages [20]. More-
over, Wang et al. [15] reported that LPS-induced IL-6
production was inhibited when HGFs were pretreated
with IL-10, suggesting that the anti-inflammatory effects of
IL-10 could affect LPS-induced pro-inflammatory cytokine
production in vivo. In our study, IL-10 levels increased in
P.g LPS-stimulated HGFs, indicating that the cells secrete
cytokines that negatively regulate inflammation. However,IL-10 levels did not change after the inhibition of miRNA-
146a and/or miRNA-146b-5p. The mechanism of IL-10 se-
cretion warrants further investigation.
miRNA-146, like many mammalian miRNAs, may tar-
get a wide spectrum of genes . It is noteworthy that
miRNA-146 has already been implicated in a number of
cellular processes [21-23]. Additionally, it has been dem-
onstrated that miRNA-146 is involved in TLR signaling
pathways [9,10]. TLR pathways are involved in innate
immunity [24]. Two key adapter molecules in the TLR
pathways, TRAF6 and IRAK1, were identified as the tar-
get genes of miRNA-146 [10,25]. TRAF6 and IRAK1
yielded high scores on the computational miRNA target
prediction algorithms. Our results indicate that miRNA-
146a and/or miRNA-146b-5p inhibitors increase IRAK1,
but not TRAF6, levels. miRNA-146b-5p had no statistical
effect on mRNA level of IRAK1, however, it could nega-
tively regulate translation process of IRAK1, protein level
had been tested significantly changed. This indicates
miRNA-146b-5p may not involve in IRAK1 binding and
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decreased after miRNA-146b-5p inhibition, it suggests
miRNA-146b-5p may regulate another target genes
and indirectly affect IRAK1 protein level.
These data indicate that miRNA-146a and miRNA-146b-5p
have different effects on IRAK1 expression. miRNAs regu-
late gene expression by binding to the 3’-UTR of target
genes [26]. Our results indicate that miRNA-146a and
miRNA-146b-5p bind to the 3’-UTR of IRAK1, suggesting
that miRNA-146a and miRNA-146b-5p directly regulate
the expression of IRAK1. However, in our study, miRNA-
146a and miRNA-146b-5p inhibitors did not result in an
increase in TRAF6, which is inconsistent with previous
studies [9]. We believe that there are other regulatory
mechanisms that control the expression of TRAF6 in
HGFs, which is a topic that warrants further investigation.
Thus, miRNA-146a and miRNA-146b-5p negatively regu-
late immune responses by inhibiting IRAK1, but not
TRAF6, expression.
Conclusions
In this study, miRNA-146a and miRNA-146b-5p are up-
regulated in P.g LPS-stimulated HGFs. The production
of pro-inflammatory cytokines, such as IL-1β, IL-6 and
TNF-α, increases after miRNA-146 inhibition, and this
inhibition is mediated by IRAK1 activation. Additionally,
miRNA-146 inhibits IRAK1 expression by binding dir-
ectly to the 3’-UTR of IRAK1. Our data suggest that
miRNA-146a and miRNA-146b-5p may be negative reg-
ulators of the immune response by inhibiting IRAK1 ex-
pression in periodontal inflammation.
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